Higher G2 sensitivity to the induction of chromosomal damage in the CHO mutant EM9 than in its parental line AA8 by camptothecin, an inhibitor of DNA topoisomerase I. 1993

F Palitti, and F Cortés, and L Bassi, and D Di Chiara, and M Fiore, and J Pinero
Dipartimento di Agrobiologia e Agrochimica, Università degli Studi della Tuscia, Viterbo, Italy.

The induction of chromosomal alterations by camptothecin (CPT), an inhibitor of DNA topoisomerase I, in the G2 stage was studied in a CHO mutant cell line EM9, which has an elevated baseline frequency of SCEs, and in its parental cell line AA8. EM9 cells were found to be more sensitive to CPT than the parental cell line. It is proposed that the effect of camptothecin in this phase of the cell cycle is caused by a 'residual' DNA synthesis which is higher in EM9 than in AA8 cells.

UI MeSH Term Description Entries
D009153 Mutagens Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. Clastogen,Clastogens,Genotoxin,Genotoxins,Mutagen
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D002166 Camptothecin An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity. Camptothecine
D002869 Chromosome Aberrations Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS. Autosome Abnormalities,Cytogenetic Aberrations,Abnormalities, Autosome,Abnormalities, Chromosomal,Abnormalities, Chromosome,Chromosomal Aberrations,Chromosome Abnormalities,Cytogenetic Abnormalities,Aberration, Chromosomal,Aberration, Chromosome,Aberration, Cytogenetic,Aberrations, Chromosomal,Aberrations, Chromosome,Aberrations, Cytogenetic,Abnormalities, Cytogenetic,Abnormality, Autosome,Abnormality, Chromosomal,Abnormality, Chromosome,Abnormality, Cytogenetic,Autosome Abnormality,Chromosomal Aberration,Chromosomal Abnormalities,Chromosomal Abnormality,Chromosome Aberration,Chromosome Abnormality,Cytogenetic Aberration,Cytogenetic Abnormality
D002875 Chromosomes In a prokaryotic cell or in the nucleus of a eukaryotic cell, a structure consisting of or containing DNA which carries the genetic information essential to the cell. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed) Chromosome
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016195 G2 Phase The period of the CELL CYCLE following DNA synthesis (S PHASE) and preceding M PHASE (cell division phase). The CHROMOSOMES are tetraploid in this point. Gap Phase 2,Second Gap Phase,G2 Phases,Gap Phase, Second,Gap Phases, Second,Phase 2, Gap,Phase, G2,Phase, Second Gap,Phases, G2,Phases, Second Gap,Second Gap Phases
D016466 CHO Cells CELL LINE derived from the ovary of the Chinese hamster, Cricetulus griseus (CRICETULUS). The species is a favorite for cytogenetic studies because of its small chromosome number. The cell line has provided model systems for the study of genetic alterations in cultured mammalian cells. CHO Cell,Cell, CHO,Cells, CHO
D059004 Topoisomerase I Inhibitors Compounds that inhibit the activity of DNA TOPOISOMERASE I. DNA Topoisomerase I Inhibitor,DNA Topoisomerase III Inhibitor,DNA Topoisomerase III Inhibitors,DNA Type 1 Topoisomerase Inhibitor,DNA Type III Topoisomerase Inhibitor,DNA Type III Topoisomerase Inhibitors,Topoisomerase 1 Inhibitor,Topoisomerase 1 Inhibitors,Topoisomerase 3 Inhibitor,Topoisomerase 3 Inhibitors,Topoisomerase I Inhibitor,Topoisomerase III Inhibitor,Topoisomerase III Inhibitors,DNA Topoisomerase I Inhibitors,DNA Type 1 Topoisomerase Inhibitors,1 Inhibitor, Topoisomerase,3 Inhibitor, Topoisomerase,3 Inhibitors, Topoisomerase,I Inhibitor, Topoisomerase,III Inhibitor, Topoisomerase,III Inhibitors, Topoisomerase,Inhibitor, Topoisomerase 1,Inhibitor, Topoisomerase 3,Inhibitor, Topoisomerase I,Inhibitor, Topoisomerase III,Inhibitors, Topoisomerase 1,Inhibitors, Topoisomerase 3,Inhibitors, Topoisomerase I,Inhibitors, Topoisomerase III

Related Publications

F Palitti, and F Cortés, and L Bassi, and D Di Chiara, and M Fiore, and J Pinero
January 1991, Mutation research,
F Palitti, and F Cortés, and L Bassi, and D Di Chiara, and M Fiore, and J Pinero
March 1989, Mutation research,
F Palitti, and F Cortés, and L Bassi, and D Di Chiara, and M Fiore, and J Pinero
August 1999, International journal of radiation biology,
F Palitti, and F Cortés, and L Bassi, and D Di Chiara, and M Fiore, and J Pinero
August 1998, Mutation research,
F Palitti, and F Cortés, and L Bassi, and D Di Chiara, and M Fiore, and J Pinero
January 2009, Chemotherapy,
F Palitti, and F Cortés, and L Bassi, and D Di Chiara, and M Fiore, and J Pinero
March 1994, Mutation research,
F Palitti, and F Cortés, and L Bassi, and D Di Chiara, and M Fiore, and J Pinero
January 1984, Mutation research,
F Palitti, and F Cortés, and L Bassi, and D Di Chiara, and M Fiore, and J Pinero
March 1995, The Journal of biological chemistry,
F Palitti, and F Cortés, and L Bassi, and D Di Chiara, and M Fiore, and J Pinero
August 1996, The Journal of cell biology,
F Palitti, and F Cortés, and L Bassi, and D Di Chiara, and M Fiore, and J Pinero
September 2001, Chemistry & biology,
Copied contents to your clipboard!